Concretely: oral semaglutide · ten days.
I understand the observation; what I do not understand is the mechanism behind it.
I have read the two review articles that come up first and both assert this without a citation to a primary source.
Can someone derive this rather than assert it?
Moving the day by 10 stretches one interval from 7 days to 17 — one interval, and then it is over. At a seven-day half-life the trough at the end of a normal week sits at 50 per cent of the preceding peak. At the end of a 17-day week it sits at 0.5^(17÷7) = 18.6 per cent: a fall of 31.4 percentage points, once, after which every interval is 7 days again. That is the entire pharmacokinetic content of the change. Whether 31.4 points of trough is worth anything is a question about your own tolerability curve rather than about the molecule. A move of 10 days is longer than the interval itself, which makes it not a shift at all but a missed dose followed by a new schedule — and it should be reasoned about as one. Timing changes are made under supervision; nothing here is medical advice.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Stated carefully, the published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
To move your dosing day, move it later and keep three days between doses.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant arithmetic is that one missed dose of a weekly agent produces a trough about half the usual, which is well inside the normal range.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
The underlying point is that to change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Two or more missed weekly doses means considering a lower restarting step.
Answering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
edited 18 Aug 2024 by Dr_Otto_Lindqvist — added the citation requested in comments
The honest answer is that a single missed weekly dose is not an event, and that two in a row starts to matter.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Set a recurring reminder attached to something you already do weekly.
The short version: for a weekly agent, take it if you are within a few days; if you are close to the next scheduled dose, skip it and resume.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
A published missed-dose window applies to a licensed product with a known content, which unverified material is not.
Never double up. Peak exposure is what drives the symptoms.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.